Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Boehringer Ingelheim
Moodys
Dow

Last Updated: September 26, 2022

Patent: 10,053,498


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,053,498
Title:Compositions comprising serum albumin and p53 peptides fusion proteins
Abstract: The present invention relates to compositions useful in inhibiting Bcl-XL or MCL-1 and disrupting p53-MDM2 and p53-MDMX interactions, and methods of using those compositions for treating a subject for conditions responsive to increasing p53 mediated activity or promoting p53 independent apoptosis, such as treating cancer. In some aspects, the compositions of this invention relate to fusion polypeptides comprising a human serum polypeptide and a p53-peptide, which can be, in some aspects, a p53 derived peptide and/or a p53 activating peptide.
Inventor(s): Li; Zhiyu (Woodstock, MD), Parker; Michelle (Leander, TX)
Assignee: University of the Sciences of Philadelphia (Philadelphia, PA)
Application Number:14/948,010
Patent Claims:see list of patent claims

Details for Patent 10,053,498

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 See Plans and Pricing 2034-11-21
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 05/05/1992 See Plans and Pricing 2034-11-21
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 02/20/1991 See Plans and Pricing 2034-11-21
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 06/28/2000 See Plans and Pricing 2034-11-21
Partner Therapeutics, Inc. LEUKINE sargramostim For Injection 103362 03/05/1991 See Plans and Pricing 2034-11-21
Partner Therapeutics, Inc. LEUKINE sargramostim Injection 103362 03/05/1991 See Plans and Pricing 2034-11-21
Wyeth Pharmaceuticals Inc. NEUMEGA oprelvekin For Injection 103694 11/25/1997 See Plans and Pricing 2034-11-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.